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The clinical benefit of a multidisciplinary clinic practice model has been well described in
a variety of medical specialties and cancer types. It proves particularly valuable when an
integrated team is needed to optimally manage patients with rare or complex neoplasms.
However, the ideal implementation of an integrated multidisciplinary care program for
translational research and education has not been well reported. Herein, we propose how
amultimodality cutaneous lymphoma (CL) clinic model can optimally manage CL patients.
We offer our perspective on this model as an efficient means for delivering patient care,
a continuing education resource for referring physicians, a conduit for translational and
clinical research, and an educational tool for medical students, house staff, and fellows.
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Introduction
In today’s changing healthcare environment, providing efficient care in a cost-effective manner
is an urgent priority. An integrated team approach resulting in improved health outcomes has
been reported in various specialties (1–6). A multidisciplinary (or multimodality) clinic is defined
as a group of health care professionals who have cognitive and procedural expertise in different
areas of care delivery and can efficiently manage complex medical conditions. Studies of disease-
focused multidisciplinary clinics have shown improved outcomes (7–9), whereby reduced mortality
has been well documented in both meta-analyses and randomized trials (10–12). Additionally,
economic analyses have demonstrated their cost-effective approach for complex patients and
diseases (1, 2).
Cutaneous lymphomas (CLs) are a rare family of extranodal non-Hodgkin’s lymphomas, a
majority of which (~70%) (13) are cutaneous T-cell lymphomas (CTCLs). CTCLs are difficult
to diagnose in early stage but are often indolent neoplasms characterized by a good response
to skin-directed therapies. However, many patients progress to more advanced stages (14) and
need systemic therapy (15). One of the challenges in CTCL is the timing and coordination of the
transition from skin-directed therapy to combined-modality therapy (skin directed+ systemic). The
transition itself is logistically complex, as it very often implies a shift from dermatology-driven
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FIGURE 1 | Patients are referred from dermatology, medical
oncology, and primary care. After patient referral, the patient revenue
specialist requests outside pathology to be reviewed at our institution,
requests medical records, and schedules appointment time. Our expert
cutaneous hematopathologist reviews outside pathology prior to initial
patient visit and then will on some occasions see the patient during first
visit. Patients in need of financial assistance are handled by our patient
assistance coordinator. The disease coordinator acts to ensure the initial
patient referral is following a smooth transition. Then, at time of the patient
visit, the medical assistant greets and escorts the patient into the room.
The new patient is checked-in by the clinic nurse who collects basic
symptoms, past-medical history, social history, family history, medication
list, and allergies. The patient is then seen by medical students/residents
and/or our clinic fellow/NP. Following a detailed discussion by the
NP/fellow, an expert cutaneous lymphoma dermatologist and
hematologist/oncologist jointly complete the visit and finalize the plan. Our
pharmacist is always available for further questions on new medications
and always counsels patients who are about to undergo new
chemotherapy. The initial patient visit is completed by our research
coordinator(s) who consent patients for our lymphoma registry and tissue
repository. After patient visit and discharge, the multimodality team
continues to work together to provide follow up care.
to oncology-driven care. Communication among specialists about
the appropriate goals of care and how to best execute the treat-
ment plan is far from adequate. Patients are often confused about
who is in charge of their care, resulting in poor satisfaction and
outcomes.
The value of amultidisciplinary caremodel in CL has been con-
sistently emphasized (16–18), but a blueprint for the design and
implementation of such a practice model is not easy to find. The
importance of a collaborative approach for advancing research has
also been underscored (19). In 2009, we designed and established
a multidisciplinary cutaneous lymphoma clinic (MCLC) at the
Ohio State University Comprehensive Cancer Center (OSUCCC)
with the goal of creating a novel integrated care delivery model
for this patient population in central Ohio as well as a resource
for referring physicians. Additional goals included the creation
of a translational research program in CTCL and establishing
the MCLC as a device to teach the principles and practice of
translational cancer research and multidisciplinary care.
The MCLC Model
Patients are referred to a centralized lymphoma scheduling office,
whose staff is trained to triage patients to the MCLC, located
at the James Cancer Hospital of the OSUCCC (Figure 1 and
Table 1). At intake, research coordinators consent patients for an
IRB-approved lymphoma database and biorepository; all archived
samples are therefore clinically annotated. The dermatologist and
hematologist–oncologist see the patient together, collaborating to
formulate the assessment and plan and jointly addressing all ques-
tions and concerns. A clinical pharmacist advises the patients on
drugs prescribed during the visit. A patient assistance coordinator
ensures the patients’ access to prescribed treatments. The MCLC
nurse provides patients with an after-visit summary, including
contact information for all resources, team members, and edu-
cational tools. In all cases, biopsies are reviewed by an expert
CL pathologist. Extra-corporeal photopheresis (ECP), radiation
therapy (RT), and bonemarrow transplantation (BMT) are closely
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TABLE 1 | Essential elements of a multimodality cutaneous lymphoma clinic.
Job title Number Function
Heme/Onc Physician 1 Formulate patient’s management plan in coordination with the dermatologist
Dermatology Physician 1 Formulate patient’s management plan in coordination with the hematologist/oncologist
Disease Coordinator 1 Patient care coordination, determine master schedule
Primary Nurse 1 Triage patient calls, prior authorizations, patient education, patient care coordination
Clinic Nurse 1 or multiple Update patient history, draw blood, triage patient calls
Medical Assistant 1 or multiple Room patients, assist with biopsies
Pharmacist 1 Educate patients on new medications, assist with prior authorizations, work with patient assistance coordinator on
financial assistance for medications
Patient Assistance Coordinator 1 Determine patient eligibility for financial assistance and file assistance applications
Nurse Practitioner 1 See patients with physicians, laboratory follow-up, medication refills, manage patient calls
Research Coordinator 1 Determine patient eligibility for biorepository, lymphoma database, consent patients
Fellow/Resident 1 or multiple See patients with physicians, laboratory follow-up, medication refills, manage patient calls, research
Pathologist 1 Review outside pathology, interpret in-house biopsies, interact with Heme/Onc and Derm physicians
Students/Rotators 2 per clinic See patients with the fellow and shadow physicians, research
Patient Revenue Cycle Specialist 1 or multiple Makes appointment for new patient referrals. Requested outside records and pathology for review. After
appointment, schedules return visits
coordinated with our colleagues. Patient satisfaction data are
collected after each visit.
Benefits of a Multidisciplinary Cutaneous
Lymphoma Clinic
Efficiency in Clinical Care Delivery
The integrated multidisciplinary care model consolidates the
expert advice of more than one specialist into a single outpatient
encounter. Furthermore, an entire team of specialized nurses,
pharmacists, and support staff is available to answer questions and
provide resources, all in one location (Table 1). A team approach
by a dermatologist and hematologist/oncologist can be achieved
with separate office visits and frequent communication; however,
management is more efficient and effective with an integrated
approach. When two specialists with extensive experience in the
recognition and management of the disease can directly commu-
nicate and make treatment decisions at a single point in time,
patient satisfaction and outcomes are superior. Furthermore, this
integrated practice model produces a high level of overlap in clin-
ical expertise between dermatology and hematology–oncology,
allowing each practitioner to efficiently and confidently step in
when the other is away, and creating support staff familiar with
all aspects of care.
A “one-stop” approach is particularly welcomed by patients
traveling from out of state but is also valuable in longitudinal
care. In total, 1256 patients (75% CTCL, 18% CBCL, 7% other),
365 of them new consultations, were seen at the MCLC over the
past 5 years. About two-thirds were referred with an established
diagnosis and one-third for a diagnostic work-up. For more than
50%, the MCLC is the primary provider and care-coordinator.
Less than 5% of the patients were discharged from the clinic
based on having a diagnosis other than CL. Patient satisfaction
data, as measured by physician performance, indicate that the
MCLC consistently ranks above its peers in the Internal Medicine
Department (mean score 98.4 out of 100) for amount of time
spent with the patient, physician’s skill and knowledge, and overall
quality of care.
A Tool for Referring Physicians
Most dermatologists and hematologist/oncologists do not rou-
tinely see or manage CL, a disease where decision-making
can often be challenging. We regularly see patients who were
treated with chemotherapy when a skin-directed approach would
have been adequate, or alternatively, patients who needed more
intensive combined-modality therapy long before referral to the
MCLC. The MCLC provides an opportunity to transmit up-
to-date information and practice tips about CL to community
physicians, including primary care providers (PCP). After each
visit, we send a detailed management plan to the patient’s physi-
cians as well as an educational packet with CME programs
geared toward our referring physicians to provide resources that
enhance their knowledge of the disease process and our treatment
recommendations.
Multimodality Clinics as an Educational Tool
As resident and medical student work hours become more
restricted, it is important to maximize the educational benefit
in the limited allowable time. For complex or rare medical con-
ditions, a multimodality clinic provides a concentrated patient
population and allows the teammembers to provide collaborative
teaching in less time. Because dedicated mentors with exten-
sive knowledge of the disease are intimately involved in patient
care, the resident or medical student spends less time on care
coordination and more time on education.
With an annual U.S. incidence of only 9.6 cases per 1 million
(15), students and residents have limited opportunities to learn
about CTCL and other CLs. Over the past 5 years, our clinic has
hosted over 50 dermatology and internal medicine residents, 5
dermatology research fellows, 10 dermatopathology fellows, 10
nurse practitioner students, and 120 medical students. Many have
commented on their limited exposure to CL throughout their
medical school and residency curriculum, further stating that
their MCLC experience was a useful tool for intensive learning.
The MCLC is a longitudinal practice component of the new OSU
Medical School curriculum, called lead, serve, inspire (LSI) (20).
LSI serves as a model to discuss the principles and challenges of
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collaborative research in a course on translational cancer research
taught by one of the authors (Pierluigi Porcu) (21). Medical stu-
dents have emphasized that the highlight of their MCLC rota-
tion was the chance to see exemplary teamwork and cooperation
among physicians from different specialties, especially as it relates
to longitudinal care for patients with a chronic disease.
Research in a Multimodality Clinic
While delivering optimal patient care is the foremost goal of
all health centers, academic programs also aim to create and
apply new knowledge that improves patient outcomes. TheMCLC
provides an ideal framework to conduct observational studies
spanning the natural history of CLs and allows longitudinal access
to clinically annotated biosamples across all stages of the dis-
ease to explore prognostic factors and biomarkers. For clinical
researchers, the MCLC is simultaneously a source of creative
inspiration – a true laboratory of ideas – and the medium and
vehicle for the execution of research projects. Firmly wedged in
between is the research laboratory, which should be infused with
as much clinical insight as possible. Thus, according to the MCLC
research model, ideas are often generated in the clinic, explored
in the laboratory, and taken back to the clinic. For patients, moti-
vation and interest in research are greatly enhanced by observing
how their personal care serves, in real time, as an engine for
discovery. Approximately 90% of the MCLC patients give consent
for our biorepository and database and, to date, we have archived
2,203 biosamples.
Conclusion
The multidisciplinary approach to patient care is underutilized
in the outpatient setting and its potential in advancing research
and education is untested. Obstacles to the implementation of
this model include (1) lack of shared outpatient physical space
for Dermatology and Hematology–Oncology, (2) billing and doc-
umentation that reflect the added value of a multidisciplinary
approach, (3) inadequate understanding of its academic worth,
(4) access to dedicated disease-specific nursing and supporting
staff, and (5) distance from the research laboratory. The analysis
presented here is limited but provides preliminary data to sup-
port this model. Metrics for performance assessment in the areas
discussed are difficult to capture and we constantly seek added
insight into how best to manage a multidisciplinary clinic. Health
care administrators and practitioners should study and adopt new
methodologies to address the added value and unique impact
of multimodality clinics, especially in the context of complex
diseases.
Acknowledgments
BH is supported by the National Cancer Institute of the National
Institutes of Health under Award Number T32CA165998 (PI
Miguel Villalona and Steven Devine). HW and PP are supported
by CA164911 and by Team CTCL/Cesidia Fund for Lymphoma
Research.
References
1. Wijeysundera HC, Machado M, Wang X, Van Der Velde G, Sikich N, Witte-
man W, et al. Cost-effectiveness of specialized multidisciplinary heart failure
clinics in Ontario, Canada. Value Health (2010) 13(8):915–21. doi:10.1111/j.
1524-4733.2010.00797.x
2. Wijeysundera HC, Austin PC, Wang X, Bennell MC, Abrahamyan L, Ko DT,
et al. The effect of multidisciplinary heart failure clinic characteristics on 1-
year postdischarge health care costs: a population-based study.MedCare (2014)
52(3):272–9. doi:10.1097/MLR.0000000000000071
3. Schmid CW, Maurer K, Schmid DM, Alon E, Spahn DR, Gantenbein AR, et al.
Prevalence of medication overuse headache in an interdisciplinary pain clinic.
J Headache Pain (2013) 14(1):4. doi:10.1186/1129-2377-14-4
4. Erskine KE, Griffith E, Degroat N, StolermanM, Silverstein LB, Hidayatallah N,
et al. An interdisciplinary approach to personalizedmedicine: case studies from
a cardiogenetics clinic. Per Med (2013) 10(1):73–80. doi:10.2217/pme.12.108
5. Miyasaki JM, Long J, Mancini D, Moro E, Fox SH, Lang AE, et al. Palliative
care for advanced Parkinson disease: an interdisciplinary clinic and new scale,
the ESAS-PD. Parkinsonism Relat Disord (2012) 18(Suppl 3):S6–9. doi:10.1016/
j.parkreldis.2012.06.013
6. Zadeh N, Getzug T, Grody WW. Diagnosis and management of familial
Mediterranean fever: integrating medical genetics in a dedicated interdisci-
plinary clinic. Genet Med (2011) 13(3):263–9. doi:10.1097/GIM.0b013e31820
e27b1
7. Komenda P, Levin A. Analysis of cardiovascular disease and kidney outcomes
in multidisciplinary chronic kidney disease clinics: complex disease requires
complex care models. Curr Opin Nephrol Hypertens (2006) 15(1):61–6. doi:10.
1097/01.mnh.0000191911.57657.35
8. Wright FC, De Vito C, Langer B, Hunter A; Expert Panel on Multidisciplinary
Cancer Conference Standards. Multidisciplinary cancer conferences: a sys-
tematic review and development of practice standards. Eur J Cancer (2007)
43(6):1002–10. doi:10.1016/j.ejca.2007.01.025
9. Hunt SA, AbrahamWT, ChinMH, Feldman AM, Francis GS, Ganiats TG, et al.
2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the
Diagnosis andManagement of Heart Failure in Adults: a report of the American
College of Cardiology Foundation/American Heart Association Task Force on
Practice Guidelines: developed in collaboration with the International Society
for Heart and Lung Transplantation. Circulation (2009) 119(14):e391–479.
doi:10.1161/CIRCULATIONAHA.109.192065
10. McAlister FA, Stewart S, Ferrua S, McMurray JJ. Multidisciplinary strategies
for the management of heart failure patients at high risk for admission: a
systematic review of randomized trials. J Am Coll Cardiol (2004) 44(4):810–9.
doi:10.1016/S0735-1097(04)01123-4
11. Arnold JM, Liu P, Demers C, Dorian P, Giannetti N, Haddad H, et al. Cana-
dian Cardiovascular Society consensus conference recommendations on heart
failure 2006: diagnosis and management. Can J Cardiol (2006) 22(1):23–45.
doi:10.1016/S0828-282X(06)70237-9
12. Hunt SA, AbrahamWT, ChinMH, Feldman AM, Francis GS, Ganiats TG, et al.
2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the
Diagnosis andManagement of Heart Failure in Adults: a report of the American
College of Cardiology Foundation/American Heart Association Task Force on
Practice Guidelines developed in collaboration with the International Society
for Heart and Lung Transplantation. J Am Coll Cardiol (2009) 53(15):e1–90.
doi:10.1016/j.jacc.2008.11.013
13. Bradford PT, Devesa SS, Anderson WF, Toro JR. Cutaneous lymphoma
incidence patterns in the United States: a population-based study of
3884 cases. Blood (2009) 113(21):5064–73. doi:10.1182/blood-2008-10-
184168
14. Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S,
et al. Survival outcomes and prognostic factors in mycosis fungoides/Sezary
syndrome: validation of the revised International Society for Cutaneous
Lymphomas/European Organisation for Research and Treatment of Cancer
staging proposal. J Clin Oncol (2010) 28(31):4730–9. doi:10.1200/JCO.2009.27.
7665
15. Wong HK, Mishra A, Hake T, Porcu P. Evolving insights in the pathogenesis
and therapy of cutaneous T-cell lymphoma (mycosis fungoides and Sezary syn-
drome). Br J Haematol (2011) 155(2):150–66. doi:10.1111/j.1365-2141.2011.
08852.x
Frontiers in Oncology | www.frontiersin.org June 2015 | Volume 5 | Article 1364
Tyler et al. Multidisciplinary care in cutaneous lymphoma
16. Kim YH. Multidisciplinary care in the management of patients with cutaneous
lymphoma: a perspective. Clin Lymphoma Myeloma Leuk (2010) 10(Suppl
2):S106–8. doi:10.3816/CLML.2010.s.021
17. Cutaneous Lymphoma Foundation (0000) [cited 2014 August 1]. Available
from: http://www.clfoundation.org
18. United States Cutaneous Lymphoma Consortium (0000) [cited 2014 August 1].
Available from: http://www.usclc.org
19. Lessin SR, Porcu P. The state of cutaneous lymphomas: a call to action. Clin
Lymphoma Myeloma Leuk (2010) 10(Suppl 2):S55–8. doi:10.3816/CLML.2010.
s.007
20. The Ohio State University College of Medicine (0000). Available from: http:
//medicine.osu.edu/students/admissions/Documents/com_viewbook.pdf
21. Porcu P. (2014). How to Develop and Run Your Own Multidisciplinary Research
Program. OSU Course Offering Catalog, O.S. University. Available from:
http://registrar.osu.edu/scheduling/SchedulingContent/2014_2015_course_
bulletin.pdf
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be
construed as a potential conflict of interest.
Copyright © 2015 Tyler, Haverkos, Hastings, Hu, Philips, Gru,Welliver,Mishra,Wong
and Porcu. This is an open-access article distributed under the terms of the Creative
Commons Attribution License (CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or licensor are credited and that
the original publication in this journal is cited, in accordance with accepted academic
practice. No use, distribution or reproduction is permitted which does not comply with
these terms.
Frontiers in Oncology | www.frontiersin.org June 2015 | Volume 5 | Article 1365
